REPORTS

Let’s Pullulate and Expand Your Business

Endometriosis Drugs Market - Global Professional Analysis and Forecast to 2026

Feb 17, 2020  |  200 PAGES  |  REPORT CODE: CMM267228
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Endometriosis Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.5% during the forecast period.

This report presents the market size and development trends by detailing the Endometriosis Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Endometriosis Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Endometriosis Drugs industry and will help you to build a panoramic view of the industrial development.

Endometriosis Drugs Market, By Type:

  • Hormonal Therapy

  • Add-back Medication

  • Progestogens

  • Chinese Herbs

Endometriosis Drugs Market, By Application:

  • Hospitals

  • Clinics

  • Research Institutes

Some of the leading players are as follows:

  • Takeda Pharmaceutical Company Limited

  • Pfizer

  • Neurocrine Biosciences

  • AbbVie

  • Evotec AG

  • AstraZeneca

  • Debiopharm Group

  • Repros Therapeutics

  • ObsEva

  • Kissei Pharmaceutical

  • ValiRx

  • Astellas Pharma

  • Roivant Sciences GmbH

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Endometriosis Drugs Market: Technology Type Analysis

  • 4.1 Endometriosis Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Endometriosis Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Hormonal Therapy

    • 4.3.2 Add-back Medication

    • 4.3.3 Progestogens

    • 4.3.4 Chinese Herbs

5 Endometriosis Drugs Market: Product Analysis

  • 5.1 Endometriosis Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Endometriosis Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Endometriosis Drugs Market: Application Analysis

  • 6.1 Endometriosis Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Endometriosis Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospitals

    • 6.3.2 Clinics

    • 6.3.3 Research Institutes

7 Endometriosis Drugs Market: Regional Analysis

  • 7.1 Endometriosis Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Endometriosis Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Takeda Pharmaceutical Company Limited

    • 9.1.1 Takeda Pharmaceutical Company Limited Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Pfizer

    • 9.2.1 Pfizer Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Neurocrine Biosciences

    • 9.3.1 Neurocrine Biosciences Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 AbbVie

    • 9.4.1 AbbVie Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Evotec AG

    • 9.5.1 Evotec AG Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 AstraZeneca

    • 9.6.1 AstraZeneca Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Debiopharm Group

    • 9.7.1 Debiopharm Group Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Repros Therapeutics

    • 9.8.1 Repros Therapeutics Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 ObsEva

    • 9.9.1 ObsEva Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Kissei Pharmaceutical

    • 9.10.1 Kissei Pharmaceutical Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 ValiRx

    • 9.11.1 ValiRx Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Astellas Pharma

    • 9.12.1 Astellas Pharma Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Roivant Sciences GmbH

    • 9.13.1 Roivant Sciences GmbH Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

 

The List of Tables and Figures (Totals 84 Figures and 160 Tables)

  • Figure Hormonal Therapy Endometriosis Drugs market, 2015 - 2026 (USD Million)

  • Figure Add-back Medication Endometriosis Drugs market, 2015 - 2026 (USD Million)

  • Figure Progestogens Endometriosis Drugs market, 2015 - 2026 (USD Million)

  • Figure Chinese Herbs Endometriosis Drugs market, 2015 - 2026 (USD Million)

  • Figure Hospitals market, 2015 - 2026 (USD Million)

  • Figure Clinics market, 2015 - 2026 (USD Million)

  • Figure Research Institutes market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Endometriosis Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Endometriosis Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Endometriosis Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Endometriosis Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Endometriosis Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Endometriosis Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Endometriosis Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Endometriosis Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Neurocrine Biosciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Evotec AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Debiopharm Group Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Repros Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ObsEva Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Kissei Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ValiRx Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Astellas Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roivant Sciences GmbH Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top